Trademark Search in Canada

BIOEPIS (COLOR)

View On IC.GC.CA

REGISTERED

on 22 Jul 2020

Last Applicant/ Owned by

SAMSUNG BIOEPIS CO. LTD.

107, Cheomdan-daero, Yeonsu-guIncheon

Serial Number

1780404 filed on 2^th May 2016

Registration Number

TMA1080678 registered on 22^nd Jul 2020

Registration expiry Date

22^nd Jul 2030

Correspondent Address

OYEN WIGGS GREEN & MUTALA LLP

480-THE STATION, 601 WEST CORDOVA STREETVANCOUVER

BRITISH COLUMBIA

V6B1G1

BIOEPIS (COLOR)

Trademark usage description

antibody formulation for treatment of immunologic deficiency syndromes and allergies, for immunoregulation, for treatment of autoimmune diseases, for Read More

Vienna Information

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

29 . 1 . 3

GreenVert

29 . 1 . 5

VioletViolet

Classification Information

Class [005]
Antibody formulation for treatment of immunologic deficiency syndromes and allergies, for immunoregulation, for treatment of autoimmune diseases, for treatment of inflammatory bowel diseases, inflammatory connective tissue diseases and injuries and asthma, for treatment of arthritis, for acting as anti-cancer agents, for treatment of cancer, for treatment of tumor, for treatment of central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and Huntington's disease, and for treatment of diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Protein formulations for treatment of immunologic deficiency syndromes and allergies, for immunoregulation, for treatment of autoimmune diseases, for treatment of inflammatory bowel diseases, inflammatory connective tissue diseases and injuries and asthma, for treatment of arthritis, for acting as anti-cancer agents, for treatment of cancer, for treatment of tumor, for treatment of central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and Huntington's disease, and for treatment of diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes and allergies; Preparations for immunoregulation; Preparations for treatment of autoimmune diseases; Preparations for treatment of inflammatory diseases, namely, pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases and asthma and pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; Preparations for treatment of arthritis; Anti-cancer agents; Preparations for treatment of cancer; Preparations for treatment of tumors; Preparations for diagnosis, namely, preparations for diagnosis of immunologic deficiency syndromes and allergies, preparations for diagnosis of autoimmune diseases, preparations for diagnosis of inflammatory bowel diseases, inflammatory connective tissue diseases and injuries and asthma, preparations for diagnosis of arthritis, preparations for diagnosis of tumor, preparations for diagnosis of central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and Huntington's disease, preparations for diagnosis of diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism and diagnostic reagents for medical diagnostic use; Preparations for treatment of central nervous system disorders, namely, pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, Huntington's disease and pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system namely brain, movement, ocular motility and spinal cord diseases; Preparations for treatment of metabolic diseases, namely, pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia and pharmaceutical preparations for the treatment of metabolic disorders, namely bulimia nervosa, anorexia, obesity and hypothyroidism; Biological tissue cultures for medical purposes.

Classification kind code

Class [042]
Pharmaceutical research and development; Bacteriological research; Biological research; Biotechnology research; Biopharmaceutical research and development; Research and development for new products for others; Material testing; Chemistry services, namely, chemistry consultation; Chemical research and analysis; Biotechnology consultation; Pharmaceutical development using animal cells; Scientific technology research in the field of plant genetics; Laboratory equipment rental.

Classification kind code

Mark Details

Serial Number

1780404

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 23 on 16^th Feb 2018	Default Removed
Submitted for opposition 12 on 16^th Feb 2018	Extension of Time
Submitted for opposition 18 on 30^th Jan 2018	Extension of Time Refused
Submitted for opposition 15 on 19^th Jul 2017	Correspondence Created
Submitted for opposition 12 on 24^th Jan 2017	Extension of Time
Submitted for opposition 22 on 14^th Jul 2016	Search Recorded
Submitted for opposition 20 on 14^th Jul 2016	Examiner's First Report
Submitted for opposition 31 on 4^th May 2016	Formalized
Submitted for opposition 1 on 3^rd May 2016	Created
Submitted for opposition 30 on 2^th May 2016	Filed